Table 3. Numbers of patients receiving systemic chemotherapy (CTx) or no chemotherapy (noCTx) stratified for treatment eras and type of systemic chemotherapy (‘5-FU'=5-Fluoruracil only, ‘Ox/Irino'=Oxaliplatin or Irinotecane-based CTx, ‘Beva/Cetux'=Bevacizumab or Cetuximab).
| noCTx | CTx | |||||
|---|---|---|---|---|---|---|
|
All eras
n=2406 (100%) |
n=1752 (72.8%) |
n=654 (27.2%) |
||||
| noPC | synPC | metaPC | noPC | synPC | metaPC | |
| |
n=1597 |
n=74 |
n=81 |
n=553 |
n=41 |
n=60 |
| |
noCTx |
CTx |
||||
|
Era of noCTx
n=733 (100%) |
n=661 (90.2%) |
n=72 (9.8%)
– 5-FU, n=72 (9.8%)
– Ox/Irino, n=0 (0%)
– Beva/Cetux, n=0 (0%) |
||||
| noPC | synPC | metaPC | noPC | synPC | metaPC | |
| |
n= 600 |
n= 25 |
n= 36 |
n=56 |
n=8 |
n=8 |
| |
noCTx |
CTx |
||||
|
Era of 5-FU only
n=1015 (100%) |
n=683 (67.3%) |
n=332 (32.7%)
– 5-FU, n=332 (32.4%)
– Ox/Irino, n=3 (0.3%)
– Beva/Cetux, n=0 (0%) |
||||
| noPC | synPC | metaPC | noPC | synPC | metaPC | |
| |
n=614 |
n=36 |
n=33 |
n=285 |
n=12 |
n=35 |
| |
noCTx |
CTx |
||||
|
Era of
contempCTx
n=658 (100%) |
n=408 (62.0%) |
n=250 (38.0%)
– 5-FU, n=144 (21.9%)
– Ox/Irino, n=92 (14.0%)
– Beva/Cetux, n=14 (2.1%) |
||||
| noPC | synPC | metaPC | noPC | synPC | metaPC | |
| n=383 | n=13 | n=12 | n=212 | n=21 | n=17 | |
Treatment eras were also stratified for patients with no (no)PC, synchronous (syn)PC and metachronous (meta)PC.